Lipid-lowering alirocumab does well in Phase III trial for Sanofi, Regeneron

10/16/2013 | New York Times (tiered subscription model), The

The cholesterol drug candidate alirocumab has shown promise in its first Phase III trial, Regeneron Pharmaceuticals and Sanofi are set to announce today. The lipid drug is the first to reach late-stage studies in a class of PCSK9 inhibitors also being developed by Pfizer and Amgen.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Tarrytown, NY
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Active Implantable Medical Device (AIMD) Product Expert
Nationwide, SL_Nationwide
Finance Manager - ENT
Jacksonville, FL
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA